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Background: Although usual interstitial pneumonia (UIP) appears to portend better survival when associated with
connective tissue disease (CTD-UIP), little is known about the presenting clinical, radiologic, and pathologic features
that differentiate pathologically confirmed UIP with CTD from idiopathic pulmonary fibrosis (IPF). In patients with
atypical radiologic and clinical features, what specific findings predict underlying IPF vs. CTD-UIP diagnosis and their
respective long term survival?
Methods: A large retrospective cohort analysis was done of consecutive patients seen from 1995 through 2010
with biopsy confirmed UIP completed or reviewed at our institution. CTD-UIP was defined by independent rheumatology
consultation with exclusion of all other secondary causes of lung fibrosis. Primary clinical data was collected and
compared for IPF and CTD-UIP along with logistic regression performed for predictors of disease likelihood and Cox
proportional hazards analysis for predictors of survival.
Results: Six hundred and twenty five patients were included in the study of which 89 had diagnosed CTD-UIP
representing 7 disease entities. Survival was better among those with CTD-UIP except in UIP associated with rheumatoid
arthritis, which had similar presenting features and survival to IPF. Predictors of underlying CTD included female gender,
younger age, positive autoimmune serology, and inconsistent presenting radiologic findings. Only age and forced vital
capacity corrected for a priori covariates were predictive of survival in CTD-UIP.
Conclusions: UIP pathology occurs frequently among patients with atypically presenting clinical and radiologic features,
and may represent IPF or CTD-UIP with improved prognosis if underlying CTD is diagnosed. Presenting radiologic and
pathologic features alone are not predictive of underlying secondary cause or survival between the two groups.
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Usual interstitial pneumonia (UIP) is characterized by
temporally heterogenous parenchymal fibrosis with archi-
tectural distortion, interstitial thickening, fibroblast foci,
and honeycombing [1]. Although a defining pathologic
finding in idiopathic pulmonary fibrosis (IPF), it has been
found in other chronic fibrotic lung disease such as the
connective tissue-disease associated interstitial lung dis-
ease (CTD-ILD) [2,3], chronic hypersensitivity pneumon-
itis (HP) [4], sarcoidosis [5], and advanced asbestosis [6].* Correspondence: moua.teng@mayo.edu
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unless otherwise stated.Current classification of the idiopathic interstitial pneu-
monias (IIP) allows not only pathological distinction of fi-
brotic disease, but implied characteristic clinical and
prognostic significance [7]. For example, it is well known
that UIP has worse prognosis than non-specific interstitial
pneumonia (NSIP), the two most commonly presenting
pathologies [8,9]. Both again may be idiopathic or associ-
ated with known etiologies, which has clinical significance
in terms of survival and response to therapy [10]. Prior
studies have suggested secondary UIP such as that seen in
certain connective-tissue diseases (CTD-UIP) may have
better prognosis and survival than IPF [2,10]. Other stud-
ies have been conflicting regarding better survival in diffi-
cult to diagnose CTD or all CTD-ILD [11,12]. Specifictd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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[13] (reticulation vs. presence of honeycombing), pulmon-
ary function testing [14,15], and physiology scores [16,17]
have been used to predict disease progression and mortality.
Surgical lung biopsy is often avoided in those with typ-
ical radiologic features consistent with IPF or clinical as-
sociation with connective-tissue disease. Even so, many
biopsies are obtained because of atypically presenting
radiologic or clinical features that do not allow for di-
rected management or discussion of a care plan. As sur-
vival in CTD-UIP has been accepted as better than IPF,
we sought to review the clinical, radiologic, and patho-
logic features of all biopsy proven UIP patients with ei-
ther IPF or CTD seen at our institution, assessing for
all-cause mortality. We hypothesized that variations in
presenting clinical, pathologic, and radiologic findings
may differentiate IPF from CTD-UIP in terms of predict-
ing diagnosis and survival.
Materials and methods
Institutional IRB approval was obtained (IRB# 11–
003506). A computer-assisted search of the pathological
database was performed and consecutive patients with
biopsy proven UIP seen at Mayo Clinic Rochester from
1995–2010 were included in the initial review. Biopsies
were obtained either at Mayo Clinic Rochester or out-
side institutions, with pathological UIP defined using
standard criteria [18] by experienced pulmonary pathol-
ogists at the time of clinical assessment.
Pathology from outside biopsies was re-reviewed at our
institution at the time of referral. Atypical pathological find-
ings in addition to underlying UIP if noted by the reading
pathologist were collated and included presence but not
predominance of any of the following: 1) poorly formed
granuloma, 2) organizing pneumonia, 3) lymphoid aggre-
gates or hyperplasia, 4) chronic inflammation, and 5) dif-
fuse alveolar damage (DAD). Patients were excluded if
pathologic findings only suggested possible UIP or had
UIP-like features but were not consistent with UIP criteria.
IPF was diagnosed according to recent consensus guide-
line as biopsy-confirmed UIP without clinical evidence of
a known secondary etiology [18]. In our cohort, all pa-
tients presenting with signs or symptoms suggestive of
rheumatologic disease underwent directed autoimmune
serologic testing, and if positive were considered undiffer-
entiated connective tissue disease (UCTD) if no further de-
finable rheumatologic disease was found. For patients with
positive screening serology but no rheumatologic symp-
toms, IPF was still considered the underlying diagnosis. If
initial CT was atypical for IPF but progressed over time to
become probable or consistent UIP along with worsened
respiratory symptoms, IPF was also considered the final
diagnosis. Underlying CTD was defined by standard cri-
teria through formal Rheumatology consultation at thetime of referral or if diagnosed previously. These included
rheumatoid arthritis (RA), scleroderma (Scl), dermato-
myositis/polymyositis (DM/PM), mixed-connective tissue
disease (MCTD), lupus erythematosus (SLE), primary
Sjögren’s syndrome, and undifferentiated connective tissue
disease (UCTD). As there is variability in the literature re-
garding UCTD definitions, we applied the broad definition
as outlined by Kinder et al. [19] in conjunction with
Rheumatology consultation. Patients with UIP associated
with hypersensitivity pneumonitis, sarcoidosis, or post-
inflammatory injury (radiation or drug toxicity) were ex-
cluded from the analysis.
Manually collected baseline clinical data included age at
time of biopsy, gender, patient reported duration of re-
spiratory symptoms prior to clinical assessment, smoker
status and pack years, history of gastroesophageal reflux
disease (GERD), and treatment with any immunosuppres-
sant or anti-inflammatory regimen defined as directed or
empiric use at a high or therapeutic level greater than four
weeks. Clinical follow-up was through date of last visit at
our institution, with date of death reviewed in the medical
record or by US Social Security Death Index (US SSDI)
search (search date 12/10/2013). Transplant free survival
and all-cause mortality were used as parameters.
Screening circulating autoimmune serologies if per-
formed by the evaluating clinician were reviewed and col-
lated, defined by positive laboratory findings in any of the
following frequently obtained serological studies: ANA
antibody titer and serology, antibody to extractable nu-
clear antigen (ENA), rheumatoid factor (RF), anti-CCP,
SS-A or La, SS-B or rho, anti-Jo-1 synthetase, anti-RNP,
anti-Scl-70, and anti-Smith antibody. Decision to obtain
screening serology studies was clinician dependent based
on presentation at the time of referral.
Pulmonary function data was reviewed for baseline pre-
senting percent predicted (% pred) pre-bronchodilator
forced vital capacity (FVC), forced expiratory volume in
one second (FEV1), total lung capacity (TLC), and diffus-
ing capacity for carbon monoxide (DLCO). Earliest pre-
senting PFT findings at the time of lung fibrosis evaluation
either at our institution or the referring institution were
analyzed if multiple studies were available.
Presenting chest tomography (CT) studies obtained
closest to the date of clinical assessment for lung fibrosis
were reviewed by one of the authors (TM) and compared
to initial Mayo reading radiologist interpretation. Classifi-
cation into one of three categories was done based on re-
cent IPF guideline [18]: 1) consistent with UIP (bibasilar
reticular, honeycombing, peripheral distribution, absence
of other features, 2) possible UIP (peripheral reticular,
bibasilar, absence of other features), and 3) probable NSIP
or inconsistent with UIP (subpleural ground glass or mild
reticulation, upper lobe distribution as well as bibasilar,
other features of atypical scarring or fibrosis).
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(Vers 10.0, Cary NC). Comparative analysis was done
using Fisher’s exact, Chi-Square, or T-test. Univariate and
multivariate logistic regression was performed adjusting
for a priori covariates of age, gender, smoker status, and
baseline percent predicted FVC and DLCO. Survival ana-
lysis for all-cause mortality was done using the Kaplan
Meier method with Log rank. Cox proportional hazards
analysis adjusted and unadjusted was done using the same
a priori covariates above to delineate predictors of death.
Missing data was reviewed and where considered random,
was adjusted using complete case analysis (list-wise dele-
tion). Subjects were censored if date of death could not be
obtained because of foreign status, underwent transplant-
ation, or were suspected alive at the time of US SSDI
search (12/10/2013). P values <0.05 were considered sta-
tistically significant.
Results
Six hundred and sixty eight consecutive patients with UIP
confirmed biopsies were reviewed for the study. Forty
three patients had UIP associated with other etiologiesTable 1 Baseline demographics
Characteristic Total (N = 625)
Age at biopsy, Yrs 63.9 ± 9.9
Gender, M/F (%) 382/243 (61/39)




Reported symptom duration prior to ILD
diagnosis, months (range)
23.9 ± 25.3 (1–180)
Clinical GERD, N (%) 362 (58)
Autoimmune serology, N (%) 180 (39%); N = 460 tested
FEV1, % pred, mean ± SD 68 ± 17; N = 552
FVC, % pred, mean ± SD 64.6 ± 17.7; N = 557
TLC, % pred, mean ± SD 67.2 ± 14.5; N = 478
DLCO, % pred, mean ± SD 47.5 ± 15.6; N = 508
HRCT at Bx, N (%) N = 584
Consistent with UIP 136 (23)
Possible UIP 266 (46)
NSIP or inconsistent UIP 182 (31)
Atypical pathology findings, N (%) 113 (18)
Treated, N (%) 438 (70)
Lung transplant, N (%) 33 (5)
Deaths, N (%) 442 (71)
Median follow-up in months, median (range) 49.5 (1–223)
All data presented as Mean ± SD unless otherwise noted.
¶P value is for IPF vs. CTD-UIP.
GERD = gastroesophageal reflux disease, ILD = interstitial lung disease, NSIP = nonsp(chronic HP, drug toxicity, sarcoidosis, and asbestosis) and
were excluded. Eighty nine were diagnosed with eventual
CTD after formal Rheumatology consultation and in-
cluded in the study, of which the majority (84%) had lung
biopsy prior to diagnosis. The remaining 536 were consid-
ered IPF. Baseline demographics and underlying CTD
diagnoses associated with UIP are presented in Tables 1
and 2. CTD-UIP patients were younger at the time of bi-
opsy (59.3 vs. 64.7 yrs (P <0.0001), predominantly female
(58% vs. 36%, P <0.0001) with less smoking history (48%
ever smokers vs. 62%, P =0.003), and had higher preva-
lence of circulating autoimmune antibodies compared
to IPF at the time of presentation (78% vs. 29%, P <0.001).
Duration of patient reported respiratory symptoms and
distribution of presenting PFT and HRCT patterns were
no different between the two groups, though CTD-
UIP patients were more likely to receive treatment
(91% vs 67%; P <0.0001). Atypical biopsy findings were
also more frequent in CTD-UIP compared to IPF (34%
vs 15%, P <0.0001) consisting predominantly of chronic
inflammation and lymphoid hyperplasia. UIP with
poorly formed granulomas, chronic inflammation, andIPF (N = 536) CTD-UIP (N = 89) P¶
64.7 ± 9.4 59.3 ± 11.5 <0.0001
345/191 (64/36) 37/52 (42/58) <0.0001
0.003
204 (38) 46 (52)
325 (60) 39 (44)
7 (2) 4 (4)
23.6 ± 24.7 (0–180) 25.3 ± 28.6 (0–120) 0.56
312 (58) 50 (56) 0.72
111 (29%); N = 378 tested 69 (78%); N = 82 tested <0.001
68.4 ± 16.8; N = 475 65.7 ± 18.2; N = 77 0.21
64.6 ± 17.3; N = 481 64 ± 19.7; N = 76 0.76
67.2 ± 14.2; N = 412 67.7 ± 16.8; N = 66 0.77
47.6 ± 15.7; N = 438 47 ± 15.4; N = 70 0.74
N = 502 N = 82 0.09
119 (24) 17 (21)
235 (47) 31 (38)
148 (29) 34 (41)
83 (15) 30 (34) <0.0001
357 (67) 81 (91) <0.0001
27 (5) 6 (7) 0.51
391 (73) 51 (57) 0.003
47.7 (1–198) 79.4 (1–223) -
ecific interstitial pneumonia, UIP = usual interstitial pneumonia.
Table 2 Specific connective-tissue disease distributions
CTD subtype (N = 89) N (%)
RA 24 (27)
SLE 2 (2)
Scleroderma (systemic sclerosis) 13 (15)
MCTD 2 (2)
DM/PM 13 (15)
Sjogren’s syndrome 5 (5)
Undifferentiated CTD 30 (34)
CTD= connective tissue disease, DM/PM=dermatomyositis/polymyositis, MCTD=
mixed connective tissue disease, RA = rheumatoid arthritis, SLE = systemic
lupus erythematosus.
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pathologic findings seen in IPF. The majority of CTD
diagnoses associated with UIP were UCTD (34%) and
RA (27%).
Among patients with pathologically confirmed UIP,
younger age, female gender, positive autoimmune ser-
ology, and non-UIP consistent radiologic patterns un-
adjusted by logistic regression were predictive of CTD
diagnosis (Table 3). After adjusting for a priori covariates
(age, gender, smoking history, percent predicted FVC and
DLCO), age, positive autoimmune serology, and inconsist-
ent CT findings remained predictive of underlying CTD.
Table 4 represents univariable and multivariable ad-
justed predictors of survival among all UIP patients. Ini-
tial unadjusted analysis suggested both smoking (HR
1.32 [1.04-1.69], P =0.023) and positive autoimmune ser-
ology were predictive of survival (HR 0.72, [0.55-0.93],
P = 0.02), though were no longer predictive after cor-
rection for age, gender, FVC, and DLCO.Table 3 Clinical predictors of IPF vs. CTD-UIP diagnosis
Univariable OR (95% CI)
Age at biopsy 1.06 (1.03-1.09)
Gender (male risk) 2.52 (1.44-4.49)
Duration of symptoms prior to biopsy 1.01 (0.99-1.02)
Positive autoimmune serology 0.08 (0.04-0.15)
FEV1, % pred 1.01 (0.99-1.03)
FVC, % pred 1.00 (0.98-1.02)
DLCO, % pred 1.01 (0.99-1.03)
TLC, % pred 0.99 (0.98-1.02)
Initial HRCT pattern
Probable UIP 1.00 (0.42-2.27)
Probable NSIP or inconsistent with UIP 0.40 (0.17-0.86)
Atypical findings on biopsy 0.36 (0.19-0.69)
% pred = percent predicted.
Complete case analysis.Given the current UIP cohort was predominantly
representative of IPF patients, subgroup analysis was
performed on CTD-UIP and IPF separately for clinical
predictors of survival (Tables 5 and 6). While age, gender,
FVC, and DLCO adjusted for a priori covariates were pre-
dictive of survival in IPF patients, only age and FVC adjusted
were predictive in CTD-UIP. Initial univariable analysis sug-
gested smoking history, FEV1, and FVC were predictive in
CTD but were no longer after correction for age and gender.
Despite female gender being predictive of CTD diagnosis,
gender was not predictive of survival among CTD patients
while in IPF male gender portended worse survival in both
univariable and multivariable analysis.
Figure 1 compares transplant-free survival from biopsy to
date of death from any cause (all-cause mortality) between
IPF and CTD-UIP. Survival among CTD-UIP was notably
better (median 79.4 vs. 47.7 months, Log rank P = 0.0005).
Figure 2 depicts survival in biopsy confirmed IPF pa-
tients stratified by 5 year intervals (a) 1995–1999, b)
2000–2004, c) 2005–2010). Survival appeared greatest in
patients biopsied from 2005–2010 (median 58.3 (42.3-
71.5) months) and least in those biopsied between 2000–
2004 (median 43.7 (34.2-48.9); (Log rank P = 0.03)).
As CTD-UIP represents a heterogenous group of
underlying diseases, and there have been recent reports
of rheumatoid related lung fibrosis representing more ag-
gressive disease [20,21], subgroup analysis of survival
among RA-UIP vs all other CTD-UIP and IPF was per-
formed and depicted in Figures 3 and 4. RA-UIP appears
to have worse survival compared to the other CTDs (me-
dian 38 vs. 103.9 months, Log rank P =0.0163) with simi-
lar survival to IPF (Log rank P =0.76). RA-UIP patients
were older and predominantly male, though with similar
baseline CT and PFT findings compared to other CTD-P value Multivariable OR (95% CI) P value
<0.0001 1.06 (1.02-1.08) 0.0012
<0.0001 1.87 (0.95-3.7) 0.07
0.27 1.01 (0.99-1.03) 0.19
<0.0001 0.09 (0.04-0.17) <0.0001
0.17 1.03 (0.97-1.10) 0.27
0.61 0.99 (0.92-1.07) 0.73
0.31 1.02 (0.99-1.05) 0.15
0.74 0.98 (0.94-1.03) 0.36
0.98 0.79 (0.29-2.05) 0.64
0.02 0.31 (0.11-0.76) 0.01
0.003 0.56 (0.27-1.22) 0.56
Table 4 Clinical predictors of death in all UIP pathology
Univariable HR (95% CI) P value Multivariable, HR (95% CI) P value
Age at biopsy 1.04 (1.02-1.05) <0.0001 1.03 (1.02-1.05) <0.0001
Male gender 1.64 (1.29-2.11) <0.001 1.55 (1.19-2.03) 0.0013
Smoking Hx 1.32 (1.04-1.69) 0.023 1.14 (0.88-1.49) 0.32
Duration of symptoms prior to biopsy 1.00 (0.99-1.01) 0.89 0.99 (0.99-1.00) 0.75
Positive autoimmune serology 0.72 (0.55-0.93) 0.02 0.83 (0.63-1.08) 0.18
GERD 0.96 (0.76-1.22) 0.75 0.94 (0.74-1.20) 0.64
FEV1, % pred 0.98 (0.98-0.99) <0.0001 0.99 (0.97-1.02) 0.64
FVC, % pred 0.98 (0.97-0.99) <0.0001 0.99 (0.98-0.99) 0.003
DLCO, % pred 0.98 (0.98-0.99) <0.0001 0.99 (0.98-0.99) 0.017
TLC, % pred 0.98 (0.97-0.99) <0.0001 0.99 (0.98-1.02) 0.78
Initial HRCT pattern
Probable UIP 0.80 (0.59-1.09) 0.15 0.83 (0.61-1.13) 0.23
Probable NSIP or inconsistent with UIP 0.88 (0.64-1.22) 0.88 0.96 (0.70-1.33) 0.79
Atypical findings on biopsy 0.78 (0.56-1.07) 0.13 0.83 (0.59-1.14) 0.27
% pred = percent predicted.
Complete case analysis.
Multivariable adjustment for age, gender, smoking hx, FVC, and DLCO.
GERD = gastroesophageal reflux disease, NSIP = nonspecific interstitial pneumonia, UIP = usual interstitial pneumonia.
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UCTD-UIP (the most frequent CTD-UIP) was also done
comparing survival to the other CTD-UIP (inclusive and
exclusive or RA-UIP) without statistical difference (Log
rank 0.144) while UCTD-UIP compared to IPF was better
(Log rank <0.0010) (Kaplan-Meier curves not shown).
As patient reported duration of symptoms prior to
diagnosis was no different between IPF and CTD-UIP,
survival analysis from time of first respiratory symptoms
did not improve survival in either cohort (data notTable 5 Subgroup analysis of clinical predictors for death in C
Univariable HR (95% CI)
Age at biopsy 1.06 (1.02-1.11)
Gender (male risk) 1.91 (0.83-4.34)
Smoking Hx 4.24 (1.76-11.80)
Duration of symptoms prior to biopsy 1.00 (0.99-1.02)
GERD 0.71 (0.31-1.60)
FEV1, % pred 0.97 (0.95-0.99)
FVC, % pred 0.98 (0.96-0.99)
DLCO, % pred 0.95 (0.92-0.99)
TLC, % pred 0.96 (0.93-0.99)
Initial HRCT pattern
Probable UIP 1.78 (0.46-11.67)
Probable NSIP or inconsistent with UIP 2.34 (0.64-14.99)
Atypical findings on biopsy 0.39 (0.11-1.02)
% pred = percent predicted.
Complete case analysis.
Multivariable adjusting for age, gender, smoking hx, FVC, and DLCO.shown). Analysis from initial clinical ILD diagnosis also
did not attenuate differences in survival.
Discussion
Our study represents the largest cohort to date of biopsy
confirmed CTD-UIP patients, comparing baseline clin-
ical features and predictors of diagnosis and survival to
biopsy confirmed IPF. Over 600 consecutive patients
were studied with the majority undergoing biopsy be-
cause of initial clinical equipoise with ILD diagnosis.TD-UIP
P value Multivariable, HR (95% CI) P value
0.0031 1.05 (1.01-1.11) 0.03
0.13 1.05 (0.39-2.80) 0.92
0.0010 2.74 (0.98-9.01) 0.06
0.69 1.01 (0.98-1.03) 0.60
0.41 0.64 (0.25-1.60) 0.33
0.04 0.99 (0.90-1.13) 0.97
0.02 0.95 (0.92-0.98) 0.01
0.005 0.99 (0.95-1.03) 0.58
0.01 0.99 (0.92-1.07) 0.88
0.44 2.06 (0.48-14.31) 0.35
0.22 2.83 (0.71-19.10) 0.15
0.06 0.68 (0.19-1.91) 0.49
Table 6 Subgroup analysis of clinical predictors of death in IPF
Univariable HR (95% CI) P value Multivariable, HR (95% CI) P value
Age at biopsy 1.03 (1.02-1.04) <0.0001 1.03 (1.01-1.04) 0.0002
Gender (male risk) 1.48 (1.15-1.93) 0.003 1.52 (1.15-2.02) 0.003
Smoking Hx 1.13 (0.88-1.46) 0.34 1.04 (0.77-1.37) 0.79
Duration of symptoms prior to biopsy 0.99 (0.99-1.00) 0.51 0.99 (0.99-1.00) 0.40
Autoimmune serology 0.89 (0.65-1.19) 0.43 0.95 (0.69-1.27) 0.72
GERD 1.05 (0.82-1.35) 0.66 1.02 (0.80-1.31) 0.87
FEV1, % pred 0.98 (0.98-0.99) 0.0004 0.99 (0.97-1.02) 0.53
FVC, % pred 0.98 (0.98-0.99) 0.0001 0.99 (0.98-0.99) 0.03
DLCO, % pred 0.99 (0.98-0.99) 0.0001 0.99 (0.98-0.99) 0.02
TLC, % pred 0.98 (0.98-0.99) 0.0012 1.00 (0.99-1.02) 0.65
Initial HRCT pattern
Probable UIP 0.76 (0.56-1.04) 0.09 0.78 (0.57-1.08) 0.13
Probable NSIP or inconsistent with UIP 0.91 (0.65-1.27) 0.56 0.96 (0.69-1.35) 0.82
Atypical findings on biopsy 0.99 (0.70-1.39) 0.98 0.96 (0.67-1.35) 0.82
% pred = percent predicted.
Complete case analysis (list-wise deletion).
Multivariable adjusting for age, gender, smoking hx, FVC, and DLCO.
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with CTD-UIP compared to IPF, despite the presence of
similar initial radiologic and PFT findings. Frequency of
positive autoimmune serologies was higher in CTD than
IPF, though still occurred in 29% of tested IPF patients.
Clinical predictors for survival in CTD-UIP were age
and FVC, compared to IPF which included additionally
gender and DLCO. Atypical or additional pathologic
findings such as organizing pneumonia, lymphoid aggre-
gates, or chronic inflammation were more frequently
seen in CTD-UIP, but did not predict survival ((HR 0.83
(0.59-1.14), P =0.27)in either cohort. In patients with
pathologically confirmed UIP, younger age, female gen-
der, presence of positive autoimmune serology, andFigure 1 Survival in IPF vs. CTD-UIP; (P = 0.0005 Log-rank).atypical radiologic findings increased the risk of under-
lying CTD diagnosis. Finally, despite CTD-UIP overall
having better survival, RA-UIP had similar survival to IPF
with worse survival compared to other CTD-UIP in our
cohort.
UIP represents a commonly found interstitial pneumo-
nia pattern whose defining features belie a heterogenously
progressive fibrotic process characterized by fibroblast
foci and honeycombing. Characteristic pathologic findings
may be diagnosed variably among evaluating pathologists,
though little is known about the prognostic features of
atypical findings such as organizing pneumonia or lymph-
oid hyperplasia in the setting of histopathologic UIP pat-
tern other than their association with CTD. Prior studiesFigure 2 Survival in IPF stratified by 5 year periods (1995–2010);
(P = 0.03 Log Rank).
Figure 3 Survival in RA-UIP vs. all other CTD-UIP; (P = 0.0163
Log Rank).
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hyperplasia [23] associated with underlying CTD, along
with decreased number of fibroblast foci [23,24]. The spe-
cific features of pathologic findings in UIP have also been
predictive of survival in IPF, in particular the frequency of
fibroblast foci [25]. The study by Park et al. compared
pathologic features among differing ILD groups and noted
improved survival among those with CTD-UIP compared
to IPF [2]. Others have found no difference in survival
among those with IPF and general CTD-ILD [12] or with
autoimmune dominant lung fibrosis [26] not fitting CTD
criteria. Little is known about the pathologic mechanisms
that lead to a common final pathway of UIP pattern yet dif-
ferent rates of disease progression and survival. An under-
standing of the perhaps presumptive inflammatory-based
mechanisms that lead to UIP in CTD-ILD compared to the
relatively unknown mechanisms in IPF may be helpful in
deciphering future IPF treatment approaches.
Our study highlights several insights in comparing bi-
opsy confirmed UIP in IPF and CTD. As most patientsFigure 4 Survival in RA-UIP vs. IPF; (P =0.76 Log Rank).with CTD-ILD have better prognosis than IPF, confirma-
tory biopsy appears unnecessary to justify treatment as
response to therapy appears better among all pathologic
subclasses. Even so, most patients undergoing biopsy do
so as a result of clinical equipoise in defining early or
atypical lung fibrosis radiologically with possible or in-
consistent IPF features and no clearly defined CTD or
secondary cause. In our cohort, presenting radiologic
and PFT findings were no different in those with sus-
pected IPF and eventual CTD. Prior studies support the
relatively high frequency of positive autoimmune serol-
ogies in IPF further confounding diagnostic evaluation
in early disease [27,28]. Our study confirms that even
among patients with UIP, female gender, younger age,
atypical CT findings, and positive autoimmune serology
were still predictive of subsequent CTD. On the other
hand UIP pathology with inconsistent UIP CT pattern
occurs relatively frequently in IPF with similar survival
to radiologically consistent disease. A recent study pro-
poses perhaps increased frequency of acute exacerbation
in IPF compared to CTD-ILD as a reason for this differ-
ence in survival, as deterioration of PFT findings over
time appeared similar between the two groups [29].
In our pathologically defined cohort, UIP associated
with RA appears to have similar clinical presentation
and survival to IPF. In particular, RA patients were older
with more male predominance compared to other CTD-
ILD, and did worse despite similar presenting PFT and
CT patterns among all CTD patients. A recent study
suggested better survival in comparison to case-matched
IPF controls who received treatment [30]. While an
NSIP CT pattern and histology are most common in
CTD-ILD, recent work suggests UIP CT features may
occur more frequently than previously noted [31] and is
highly consistent with underlying UIP pathology [20].
Such radiologic features of advanced disease appear pre-
dictive of survival similar to IPF, though in our cohort,
similar presenting radiologic patterns were seen between
RA-UIP patients and other CTD-UIP (predominantly
atypical or probable UIP CT findings). As UIP pathology
appears to bode worse survival, confirmatory biopsy in
this subset of CTD-ILD particularly with atypical CT
may not be unreasonable. Underlying mechanisms as to
why RA-UIP may do poorly is currently unknown and
the subject of ongoing study.
Survival in IPF is known to be variable and may be af-
fected by multiple factors including disease severity at
the time of presentation and access to tertiary or expert
care with earlier assessment [32]. Whether earlier diag-
nosis affects outcome remains tentative, as most patients
with consistent UIP pattern on CT likely represent more
advanced disease with worse survival. We note survival
by 5 year intervals in our cohort suggest recently biop-
sied patients had better survival than those biopsied a
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haps earlier diagnosis and better recognition of disease,
but unlikely secondary to improved treatments. One hy-
pothesis is perhaps a trend away from empiric steroids
and other anti-inflammatory agents in recent years for the
treatment of IPF, which may have had previously deleteri-
ous effects on survival outside of disease progression itself.
This is reflected in the comparatively worse survival of
those on combination anti-inflammatory therapy with
prednisone and azathioprine as found with the PANTHER
trial [33].
Limitations of our study include its retrospective ap-
proach and the inclusion of only biopsy confirmed pa-
tients. As the intent of the study was to assess the role
of underlying pathology and its implication in prognosis
and response to treatment, application of our findings to
clinically suspected IPF or CTD-ILD patients without
confirmed biopsy may be limited. NSIP still remains the
dominant pathologic finding in CTD-ILD where survival
among non-biopsied patients may be more influenced
by this than the noted improved survival of CTD-UIP.
Our cohorts suggest that the presence of diagnosed CTD
and not UIP itself appears to portend better survival even
among patients with initially similar pathology, radiology,
and PFT findings. Finally, while CTD-UIP other than RA-
UIP had better survival than IPF, seven rheumatologic dis-
eases were represented with heterogenous and unique
clinical courses, whose survival or response to therapy
may be marked by other variables outside of lung fibrosis.
In summary, our study is the largest to date comparing
survival in IPF vs CTD-UIP, noting clinical predictors of
disease progression with improved survival among those
with CTD-UIP except RA-UIP which had similar survival
to IPF. Clinical manifestations among those with unspeci-
fied UIP that may predict CTD include female gender,
younger age, inconsistent radiologic findings, and positive
autoimmune serology. Radiologic and pathologic findings
alone and corrected were not predictive of either CTD-
ILD diagnosis or prognosis.
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